Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): a single-centre randomized, placebo-controlled trial

Mohan et al., Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2021.08.021 (date from preprint), RIVET-COV, CTRI/2020/06/026001
Feb 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Discharge at day 14, 24mg 62% Improvement Relative Risk Discharge at day 14, 12mg 44% Clinical worsening, 24mg 32% Clinical worsening, 12mg 55% Viral clearance, 24mg, d.. 24% primary Viral clearance, 12mg, d.. 6% Viral clearance, 24m.. (b) 10% Viral clearance, 12m.. (b) -3% Ivermectin  RIVET-COV  EARLY TREATMENT  DB RCT Is early treatment with ivermectin beneficial for COVID-19? Double-blind RCT 157 patients in India (July - September 2020) Improved recovery (p=0.27) and viral clearance (p=0.18), not sig. c19ivm.org Mohan et al., J. Infection and Chemoth.., Feb 2021 Favorsivermectin Favorscontrol 0 0.5 1 1.5 2+
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now with p < 0.00000000001 from 104 studies, recognized in 23 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19ivm.org
RCT in India with low risk patients, comparing 24mg ivermectin, 12mg ivermectin, and placebo showing non-statistically significant improvements in recovery and PCR+ status (day 5 both arms, day 7 24mg only) with treatment, and showing greater improvement for the higher dose arm. Viral load decline was similar in all arms - absolute values are lower for ivermectin in a dose-dependent manner, however the baseline value for the ivermectin groups was lower, leaving less room for change. There were no deaths or use of mechanical ventilation. There were no serious adverse events. Note that our pre-specified protocol prioritizes clinical outcomes over PCR results.
Viral load measured by PCR may not accurately reflect infectious virus measured by viral culture. Porter et al. show that viral load early in infection was correlated with infectious virus, but viral load late in infection could be high even with low or undetectable infectious virus. Assessing viral load later in infection may underestimate reductions in infectious virus with treatment.
This is the 16th of 51 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.00000015.
This is the 35th of 104 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 1 sextillion).
risk of no discharge at day 14, 62.5% lower, RR 0.38, p = 0.27, treatment 2 of 40 (5.0%), control 6 of 45 (13.3%), NNT 12, 24mg.
risk of no discharge at day 14, 43.8% lower, RR 0.56, p = 0.49, treatment 3 of 40 (7.5%), control 6 of 45 (13.3%), NNT 17, 12mg.
risk of clinical worsening, 32.5% lower, RR 0.68, p = 0.72, treatment 3 of 40 (7.5%), control 5 of 45 (11.1%), NNT 28, 24mg.
risk of clinical worsening, 55.0% lower, RR 0.45, p = 0.44, treatment 2 of 40 (5.0%), control 5 of 45 (11.1%), NNT 16, 12mg.
risk of no viral clearance, 23.8% lower, RR 0.76, p = 0.18, treatment 21 of 40 (52.5%), control 31 of 45 (68.9%), NNT 6.1, day 5, 24mg, primary outcome.
risk of no viral clearance, 5.6% lower, RR 0.94, p = 0.82, treatment 26 of 40 (65.0%), control 31 of 45 (68.9%), NNT 26, day 5, 12mg.
risk of no viral clearance, 10.3% lower, RR 0.90, p = 0.65, treatment 20 of 36 (55.6%), control 26 of 42 (61.9%), NNT 16, day 7, 24mg.
risk of no viral clearance, 3.2% higher, RR 1.03, p = 1.00, treatment 23 of 36 (63.9%), control 26 of 42 (61.9%), day 7, 12mg.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Mohan et al., 2 Feb 2021, Double Blind Randomized Controlled Trial, India, peer-reviewed, 27 authors, study period 28 July, 2020 - 29 September, 2020, average treatment delay 5.0 days, dosage 400μg/kg single dose, 200μg/kg also tested, trial CTRI/2020/06/026001 (RIVET-COV).
This PaperIvermectinAll
Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre randomized, placebo-controlled trial
Prof Anant Mohan, Tejas Pawan Tiwari, Tejas Menon Suri, Saurabh Mittal, Ankit Patel, Ujjalkumar Avinash Jain, Thirumurthy Velpandian, Ujjalkumar Subhash Das, Tarun Krishna Boppana, Sushil Ravindra Mohan Pandey, Sushil Suresh Shelke, Angel Rajan Singh, Sushma Bhatnagar, Shet Masih, Shelly Mahajan, Tanima Dwivedi, Biswajeet Sahoo, Anuja Pandit, Shweta Bhopale, Saurabh Vig, Ritu Gupta, Karan Madan, Vijay Hadda, Nishkarsh Gupta, Rakesh Garg, Ved Prakash Meena, Randeep Guleria
Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2021.08.021
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
CONFLICTS OF INTEREST: None to declare
References
Ahmed, Karim, Ross, Hossain, Clemens et al., A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis IJID Off Publ Int Soc Infect Dis
Borghesi, Maroldi, COVID-19 outbreak in Italy: experimental chest X-ray scoring system for quantifying and monitoring disease progression, Radiol Med
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res
Chaccour, Casellas, Matteo, Pineda, Fernandez-Montero et al., The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial
Changeux, Amoura, Rey, Miyara, A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications, C R Biol
Chiu, Taub, Sestokas, Lu, Jacob, Comparative in vivo and in vitro metabolism of ivermectin in steers, sheep, swine, and rat, Drug Metab Rev
De, Cg, Gregianin, Burger, Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection, Leuk Lymphoma
Dong, Du, Gardner, An interactive web-based dashboard to track COVID-19 in real time, Lancet Infect Dis
Guzzo, Furtek, Porras, Chen, Tipping et al., Tolerability, and Pharmacokinetics of Escalating High Doses of Ivermectin in Healthy Adult Subjects, Pharmacokinet Pharmacodyn
Heidary, Gharebaghi, Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen, J Antibiot
J O U R N A L P R E, -p r o o f
Krause, Buisson, Bertrand, Corringer, Galzi et al., Ivermectin: a positive allosteric effector of the alpha7 neuronal nicotinic acetylcholine receptor, Mol Pharmacol
Lespine, Alvinerie, Sutra, Pors, Chartier, Influence of the route of administration on efficacy and tissue distribution of ivermectin in goat, Vet Parasitol
Lifschitz, Virkel, Sallovitz, Sutra, Galtier et al., Comparative distribution of ivermectin and doramectin to parasite location tissues in cattle, Vet Parasitol
López-Medina, López, Hurtado, Dávalos, Ramirez et al., Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial, JAMA
Mastrangelo, Pezzullo, Burghgraeve, Kaptein, Pastorino et al., Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug, J Antimicrob Chemother
Omura, Crump, Ivermectin: panacea for resource-poor communities?, Trends Parasitol
Peña-Silva, Duffull, Steer, Jaramillo-Rincon, Gwee et al., Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19, Br J Clin Pharmacol
Podder, Chowdhury, Sina, Haque, Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study, IMC J Med Sci
Rahman, Iqbal, Islam, Niaz, Hussain et al., Comparison of Viral Clearance between Ivermectin with Doxycycline and Hydroxychloroquine with Azithromycin in COVID-19 Patients, J Bangladesh Coll Physicians Surg
Rajter, Sherman, Fatteh, Vogel, Sacks et al., Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease, Chest
Rao, Manissero, Steele, Pareja, A Narrative Systematic Review of the Clinical Utility of Cycle Threshold Values in the Context of COVID-19, Infect Dis Ther
Samaha, Mouawia, Fawaz, Hassan, Salami et al., Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon, Viruses
Shu, Onwujekwe, Okonkwo, Do alcoholic beverages enhance availability of ivermectin?, Eur J Clin Pharmacol
Wagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem J
Wolff, Nee, Hickey, Marschollek, Risk factors for Covid-19 severity and fatality: a structured literature review, Infection
Yang, Atkinson, Wang, Lee, Bogoyevitch et al., The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer, Antiviral Res
Zhou, Yu, Du, Fan, Liu et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, The Lancet
{ 'indexed': {'date-parts': [[2024, 4, 8]], 'date-time': '2024-04-08T02:13:59Z', 'timestamp': 1712542439062}, 'reference-count': 28, 'publisher': 'Elsevier BV', 'issue': '12', 'license': [ { 'start': { 'date-parts': [[2021, 12, 1]], 'date-time': '2021-12-01T00:00:00Z', 'timestamp': 1638316800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}], 'funder': [ { 'DOI': '10.13039/501100001843', 'name': 'Science and Engineering Research Board', 'doi-asserted-by': 'publisher', 'award': ['CVD/2020/001105']}, { 'DOI': '10.13039/501100006143', 'name': 'Department of Science and Technology, Government of Kerala', 'doi-asserted-by': 'publisher'}, { 'DOI': '10.13039/501100001409', 'name': 'Department of Science and Technology, Ministry of Science and Technology, India', 'doi-asserted-by': 'publisher'}], 'content-domain': { 'domain': [ 'clinicalkey.jp', 'clinicalkey.com', 'jiac-j.com', 'clinicalkey.es', 'clinicalkey.fr', 'clinicalkey.com.au', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2021, 12]]}, 'DOI': '10.1016/j.jiac.2021.08.021', 'type': 'journal-article', 'created': {'date-parts': [[2021, 8, 25]], 'date-time': '2021-08-25T05:04:47Z', 'timestamp': 1629867887000}, 'page': '1743-1749', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 28, 'title': 'Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A single-centre ' 'randomized, placebo-controlled trial', 'prefix': '10.1016', 'volume': '27', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-2383-9437', 'authenticated-orcid': False, 'given': 'Anant', 'family': 'Mohan', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-5136-4221', 'authenticated-orcid': False, 'given': 'Pawan', 'family': 'Tiwari', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-2010-4651', 'authenticated-orcid': False, 'given': 'Tejas Menon', 'family': 'Suri', 'sequence': 'additional', 'affiliation': []}, {'given': 'Saurabh', 'family': 'Mittal', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ankit', 'family': 'Patel', 'sequence': 'additional', 'affiliation': []}, {'given': 'Avinash', 'family': 'Jain', 'sequence': 'additional', 'affiliation': []}, {'given': 'Thirumurthy', 'family': 'Velpandian', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-3749-4975', 'authenticated-orcid': False, 'given': 'Ujjalkumar Subhash', 'family': 'Das', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-9970-3712', 'authenticated-orcid': False, 'given': 'Tarun Krishna', 'family': 'Boppana', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ravindra Mohan', 'family': 'Pandey', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sushil Suresh', 'family': 'Shelke', 'sequence': 'additional', 'affiliation': []}, {'given': 'Angel Rajan', 'family': 'Singh', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sushma', 'family': 'Bhatnagar', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shet', 'family': 'Masih', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shelly', 'family': 'Mahajan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Tanima', 'family': 'Dwivedi', 'sequence': 'additional', 'affiliation': []}, {'given': 'Biswajeet', 'family': 'Sahoo', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-4609-903X', 'authenticated-orcid': False, 'given': 'Anuja', 'family': 'Pandit', 'sequence': 'additional', 'affiliation': []}, {'given': 'Shweta', 'family': 'Bhopale', 'sequence': 'additional', 'affiliation': []}, {'given': 'Saurabh', 'family': 'Vig', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-5364-4086', 'authenticated-orcid': False, 'given': 'Ritu', 'family': 'Gupta', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-5330-6391', 'authenticated-orcid': False, 'given': 'Karan', 'family': 'Madan', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-5820-3685', 'authenticated-orcid': False, 'given': 'Vijay', 'family': 'Hadda', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nishkarsh', 'family': 'Gupta', 'sequence': 'additional', 'affiliation': []}, {'given': 'Rakesh', 'family': 'Garg', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ved Prakash', 'family': 'Meena', 'sequence': 'additional', 'affiliation': []}, {'given': 'Randeep', 'family': 'Guleria', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'issue': '5', 'key': '10.1016/j.jiac.2021.08.021_bib1', 'doi-asserted-by': 'crossref', 'first-page': '533', 'DOI': '10.1016/S1473-3099(20)30120-1', 'article-title': 'An interactive web-based dashboard to track COVID-19 in real time', 'volume': '20', 'author': 'Dong', 'year': '2020', 'journal-title': 'Lancet Infect Dis'}, { 'issue': '9', 'key': '10.1016/j.jiac.2021.08.021_bib2', 'doi-asserted-by': 'crossref', 'first-page': '445', 'DOI': '10.1016/j.pt.2014.07.005', 'article-title': 'Ivermectin: panacea for resource-poor communities?', 'volume': '30', 'author': 'Omura', 'year': '2014', 'journal-title': 'Trends Parasitol'}, { 'issue': '3', 'key': '10.1016/j.jiac.2021.08.021_bib3', 'doi-asserted-by': 'crossref', 'first-page': '851', 'DOI': '10.1042/BJ20120150', 'article-title': 'Ivermectin is a specific inhibitor of importin α/β-mediated nuclear ' 'import able to inhibit replication of HIV-1 and dengue virus', 'volume': '443', 'author': 'Wagstaff', 'year': '2012', 'journal-title': 'Biochem J'}, { 'issue': '8', 'key': '10.1016/j.jiac.2021.08.021_bib4', 'doi-asserted-by': 'crossref', 'first-page': '1884', 'DOI': '10.1093/jac/dks147', 'article-title': 'Ivermectin is a potent inhibitor of flavivirus replication specifically ' 'targeting NS3 helicase activity: new prospects for an old drug', 'volume': '67', 'author': 'Mastrangelo', 'year': '2012', 'journal-title': 'J Antimicrob Chemother'}, { 'key': '10.1016/j.jiac.2021.08.021_bib5', 'doi-asserted-by': 'crossref', 'first-page': '104760', 'DOI': '10.1016/j.antiviral.2020.104760', 'article-title': 'The broad spectrum antiviral ivermectin targets the host nuclear ' 'transport importin α/β1 heterodimer', 'volume': '177', 'author': 'Yang', 'year': '2020', 'journal-title': 'Antivir Res'}, { 'key': '10.1016/j.jiac.2021.08.021_bib6', 'doi-asserted-by': 'crossref', 'first-page': '104787', 'DOI': '10.1016/j.antiviral.2020.104787', 'article-title': 'The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 ' 'in vitro', 'volume': '178', 'author': 'Caly', 'year': '2020', 'journal-title': 'Antivir Res'}, { 'issue': '2–3', 'key': '10.1016/j.jiac.2021.08.021_bib7', 'doi-asserted-by': 'crossref', 'first-page': '289', 'DOI': '10.3109/03602538708998309', 'article-title': 'Comparative in vivo and in vitro metabolism of ivermectin in steers, ' 'sheep, swine, and rat', 'volume': '18', 'author': 'Chiu', 'year': '1987', 'journal-title': 'Drug Metab Rev'}, { 'issue': '4', 'key': '10.1016/j.jiac.2021.08.021_bib8', 'doi-asserted-by': 'crossref', 'first-page': '327', 'DOI': '10.1016/S0304-4017(99)00175-2', 'article-title': 'Comparative distribution of ivermectin and doramectin to parasite ' 'location tissues in cattle', 'volume': '87', 'author': 'Lifschitz', 'year': '2000', 'journal-title': 'Vet Parasitol'}, { 'key': '10.1016/j.jiac.2021.08.021_bib9', 'first-page': '214', 'article-title': 'A five-day course of ivermectin for the treatment of COVID-19 may ' 'reduce the duration of illness', 'volume': '103', 'author': 'Ahmed', 'year': '2021', 'journal-title': 'Int J Infect Dis IJID Off Publ Int Soc Infect Dis'}, { 'issue': '6', 'key': '10.1016/j.jiac.2021.08.021_bib10', 'doi-asserted-by': 'crossref', 'first-page': '989', 'DOI': '10.3390/v13060989', 'article-title': 'Effects of a single dose of ivermectin on viral and clinical outcomes ' 'in asymptomatic SARS-CoV-2 infected subjects: a pilot clinical trial in ' 'Lebanon', 'volume': '13', 'author': 'Samaha', 'year': '2021', 'journal-title': 'Viruses'}, { 'issue': '14', 'key': '10.1016/j.jiac.2021.08.021_bib11', 'doi-asserted-by': 'crossref', 'first-page': '1426', 'DOI': '10.1001/jama.2021.3071', 'article-title': 'Effect of ivermectin on time to resolution of symptoms among adults ' 'with mild COVID-19: a randomized clinical trial', 'volume': '325', 'author': 'López-Medina', 'year': '2021', 'journal-title': 'J Am Med Assoc'}, { 'key': '10.1016/j.jiac.2021.08.021_bib12', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.eclinm.2020.100720', 'article-title': 'The effect of early treatment with ivermectin on viral load, symptoms ' 'and humoral response in patients with non-severe COVID-19: a pilot, ' 'double-blind, placebo-controlled, randomized clinical trial', 'author': 'Chaccour', 'year': '2021', 'journal-title': 'EClinicalMedicine'}, { 'issue': '10', 'key': '10.1016/j.jiac.2021.08.021_bib13', 'doi-asserted-by': 'crossref', 'first-page': '2536', 'DOI': '10.1080/10428194.2020.1786559', 'article-title': 'Continuous high-dose ivermectin appears to be safe in patients with ' 'acute myelogenous leukemia and could inform clinical repurposing for ' 'COVID-19 infection', 'volume': '61', 'author': 'de Castro', 'year': '2020', 'journal-title': 'Leuk Lymphoma'}, { 'key': '10.1016/j.jiac.2021.08.021_bib14', 'unstructured': 'Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, Clineschmidt CM, et ' 'al. Safety, tolerability, and pharmacokinetics of escalating high doses ' 'of ivermectin in healthy adult subjects. Pharmacokinet Pharmacodyn. ' ':12.'}, { 'key': '10.1016/j.jiac.2021.08.021_bib15', 'first-page': '1', 'article-title': 'COVID-19 outbreak in Italy: experimental chest X-ray scoring system for ' 'quantifying and monitoring disease progression', 'author': 'Borghesi', 'year': '2020', 'journal-title': 'Radiol Med'}, { 'issue': '3–4', 'key': '10.1016/j.jiac.2021.08.021_bib16', 'doi-asserted-by': 'crossref', 'first-page': '251', 'DOI': '10.1016/j.vetpar.2004.11.028', 'article-title': 'Influence of the route of administration on efficacy and tissue ' 'distribution of ivermectin in goat', 'volume': '128', 'author': 'Lespine', 'year': '2005', 'journal-title': 'Vet Parasitol'}, { 'key': '10.1016/j.jiac.2021.08.021_bib17', 'series-title': 'COVID-19 therapeutic trial synopsis', 'author': 'WHO R&D Blueprint novel Coronavirus', 'year': '2020'}, { 'key': '10.1016/j.jiac.2021.08.021_bib18', 'first-page': '14476', 'article-title': 'Pharmacokinetic considerations on the repurposing of ivermectin for ' 'treatment of COVID‐19', 'author': 'Peña‐Silva', 'year': '2020', 'journal-title': 'Br J Clin Pharmacol'}, { 'issue': '5', 'key': '10.1016/j.jiac.2021.08.021_bib19', 'doi-asserted-by': 'crossref', 'first-page': '437', 'DOI': '10.1007/s002280000120', 'article-title': 'Do alcoholic beverages enhance availability of ivermectin?', 'volume': '56', 'author': 'Shu', 'year': '2000', 'journal-title': 'Eur J Clin Pharmacol'}, { 'issue': '2', 'key': '10.1016/j.jiac.2021.08.021_bib20', 'doi-asserted-by': 'crossref', 'first-page': '283', 'DOI': '10.1124/mol.53.2.283', 'article-title': 'Ivermectin: a positive allosteric effector of the alpha7 neuronal ' 'nicotinic acetylcholine receptor', 'volume': '53', 'author': 'Krause', 'year': '1998', 'journal-title': 'Mol Pharmacol'}, { 'issue': '1', 'key': '10.1016/j.jiac.2021.08.021_bib21', 'first-page': '33', 'article-title': 'A nicotinic hypothesis for Covid-19 with preventive and therapeutic ' 'implications', 'volume': '343', 'author': 'Changeux', 'year': '2020', 'journal-title': 'C R Biol'}, { 'key': '10.1016/j.jiac.2021.08.021_bib22', 'first-page': '14', 'article-title': 'Outcome of ivermectin treated mild to moderate COVID-19 cases: a ' 'single-centre, open-label, randomised controlled study', 'author': 'Podder', 'year': '2020', 'journal-title': 'IMC J Med Sci'}, { 'key': '10.1016/j.jiac.2021.08.021_bib23', 'first-page': '1', 'article-title': 'A narrative systematic review of the clinical utility of cycle ' 'threshold values in the context of COVID-19', 'author': 'Rao', 'year': '2020', 'journal-title': 'Infect Dis Ther'}, { 'key': '10.1016/j.jiac.2021.08.021_bib24', 'article-title': 'Use of ivermectin is associated with lower mortality in hospitalized ' 'patients with coronavirus disease 2019', 'author': 'Rajter', 'year': '2020', 'journal-title': 'Chest'}, { 'issue': '9', 'key': '10.1016/j.jiac.2021.08.021_bib25', 'doi-asserted-by': 'crossref', 'first-page': '593', 'DOI': '10.1038/s41429-020-0336-z', 'article-title': 'Ivermectin: a systematic review from antiviral effects to COVID-19 ' 'complementary regimen', 'volume': '73', 'author': 'Heidary', 'year': '2020', 'journal-title': 'J Antibiot (Tokyo)'}, { 'key': '10.1016/j.jiac.2021.08.021_bib26', 'doi-asserted-by': 'crossref', 'first-page': '5', 'DOI': '10.3329/jbcps.v38i0.47514', 'article-title': 'Comparison of viral clearance between ivermectin with doxycycline and ' 'hydroxychloroquine with azithromycin in COVID-19 patients', 'author': 'Rahman', 'year': '2020', 'journal-title': 'J Bangladesh Coll Phys Surg'}, { 'key': '10.1016/j.jiac.2021.08.021_bib27', 'doi-asserted-by': 'crossref', 'first-page': '1054', 'DOI': '10.1016/S0140-6736(20)30566-3', 'article-title': 'Clinical course and risk factors for mortality of adult inpatients with ' 'COVID-19 in Wuhan, China: a retrospective cohort study', 'volume': '395', 'author': 'Zhou', 'year': '2020', 'journal-title': 'Lancet'}, { 'key': '10.1016/j.jiac.2021.08.021_bib28', 'first-page': '1', 'article-title': 'Risk factors for Covid-19 severity and fatality: a structured ' 'literature review', 'author': 'Wolff', 'year': '2020', 'journal-title': 'Infection'}], 'container-title': 'Journal of Infection and Chemotherapy', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S1341321X21002397?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S1341321X21002397?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2021, 10, 25]], 'date-time': '2021-10-25T17:28:34Z', 'timestamp': 1635182914000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S1341321X21002397'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 12]]}, 'references-count': 28, 'journal-issue': {'issue': '12', 'published-print': {'date-parts': [[2021, 12]]}}, 'alternative-id': ['S1341321X21002397'], 'URL': 'http://dx.doi.org/10.1016/j.jiac.2021.08.021', 'relation': {}, 'ISSN': ['1341-321X'], 'subject': ['Infectious Diseases', 'Pharmacology (medical)', 'Microbiology (medical)'], 'container-title-short': 'Journal of Infection and Chemotherapy', 'published': {'date-parts': [[2021, 12]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A ' 'single-centre randomized, placebo-controlled trial', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'Journal of Infection and Chemotherapy', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.jiac.2021.08.021', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2021 Japanese Society of Chemotherapy and The Japanese Association for ' 'Infectious Diseases. Published by Elsevier Ltd. All rights reserved.', 'name': 'copyright', 'label': 'Copyright'}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit